Results 321 to 330 of about 83,254 (357)

Janus kinase inhibitors role in bone remodeling

Journal of Cellular Physiology, 2019
AbstractJanus kinases (JAKs) play a pleiotropic role in several important physiological processes, such as cell maturation, cell proliferation, and cell death, via providing transmission signals from several molecules, such as cytokines, interferons, hormones, and growth factors, to the nucleus. Bone physiology and remodeling are markedly influenced by
Nicola Maruotti, Addolorata Corrado, Cinzia Rotondo, Francesco Paolo Cantatore   +3 more
openaire   +3 more sources

Janus kinase inhibitors for rheumatoid arthritis

Current Opinion in Chemical Biology, 2016
Treatment of autoimmune diseases, such as rheumatoid arthritis (RA), has advanced substantially over the past decade with the development of biologics targeting inflammatory cytokines. Recent progress in treating RA has been achieved with janus kinase (JAK) inhibitors (Jakinibs), an orally available disease-modifying anti-rheumatic drug targeting the ...
openaire   +2 more sources

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources

Janus kinases inhibitors for treating patients with rhupus

Joint Bone Spine, 2020
HIGHLIGHTS • baricitinib and tofacitinib are effective in patients with Rhupus • JAK inhibitors are an alternative option in patients with refractory SLE • JAK inhibitors have a steroid-sparing effect in patients with ...
Garufi C., Mancuso S., Spinelli F. R., Truglia S., Ceccarelli F., Alessandri C., Conti F.   +6 more
openaire   +2 more sources

Janus kinases inhibitors

Cahiers Santé Médecine Thérapeutique, 2022
El Mehdi Boudhar, M El Mandour, Abdelhafid Elguich, Hajar Sahimi, Hasna Hassikou   +4 more
openaire   +1 more source

Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors

Current Pharmaceutical Design, 2004
Here we discuss the therapeutic potential of Janus kinase 3 (JAK3) inhibitors as a new class of immunomodulatory agents with immunosuppressive, anti-inflammatory, anti-allergic, anti-thrombotic and anti-leukemic properties. JAKs are abundantly expressed in primary leukemic cells from children with ALL (acute lymphoblastic leukemia) and are crucial for ...
M, Cetkovic-Cvrlje, H E, Tibbles
openaire   +2 more sources

Thromboembolism and Janus Kinase Inhibitors

Drug Safety, 2020
Fowzia Ibrahim, David L. Scott
openaire   +3 more sources

Janus Kinase (JAK) Inhibitors

2022
Courtney E. Heron, Lindsay C. Strowd, Steven R. Feldman   +2 more
openaire   +1 more source

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly